A Study to Assess the Safety and Effectiveness of Tacrolimus Cream in the Treatment of Psoriasis
NCT ID: NCT00293930
Last Updated: 2007-12-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
645 participants
INTERVENTIONAL
2006-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tacrolimus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Disease on only elbows, knees, and scalp
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Astellas Pharma US, Inc.
INDUSTRY
Astellas Pharma Inc
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
J Rico, MD
Role: STUDY_DIRECTOR
Astellas Pharma US, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hot Springs, Arkansas, United States
San Diego, California, United States
San Francisco, California, United States
Longmont, Colorado, United States
New Haven, Connecticut, United States
Washington D.C., District of Columbia, United States
Miami, Florida, United States
Newnan, Georgia, United States
Evansville, Indiana, United States
South Bend, Indiana, United States
Iowa City, Iowa, United States
St Louis, Missouri, United States
New York, New York, United States
Rochester, New York, United States
Winston-Salem, North Carolina, United States
Cincinnati, Ohio, United States
Portland, Oregon, United States
Philadelphia, Pennsylvania, United States
Nashville, Tennessee, United States
Bryan, Texas, United States
Dallas, Texas, United States
Galveston, Texas, United States
Burlington, Vermont, United States
Lynchburg, Virginia, United States
Dayton, Washington, United States
Madison, Wisconsin, United States
Winnipeg, Manitoba, Canada
St. John's, Newfoundland and Labrador, Canada
North Bay, Ontario, Canada
Waterloo, Ontario, Canada
Windsor, Ontario, Canada
Saskatoon, Saskatchewan, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
04-0-205
Identifier Type: -
Identifier Source: org_study_id